Figure 1. Research Method Flow Chart 12
Figure 2. Breakdown of Primary Research 14
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 18
Figure 5. North America Active Pharmaceutical Ingredients (API) Market, 2019-2026, $ bn 20
Figure 6. Primary Drivers and Impact Factors of North America Active Pharmaceutical Ingredients (API) Market 21
Figure 7. GDP per capita in the World, 1960-2018, $ thousand 24
Figure 8. Forecast of Middle-class Population by Region, 2015-2030, million 24
Figure 9. Primary Restraints and Impact Factors of North America Active Pharmaceutical Ingredients (API) Market 25
Figure 10. Investment Opportunity Analysis 29
Figure 11. Porter’s Fiver Forces Analysis of North America Active Pharmaceutical Ingredients (API) Market 32
Figure 12. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2019-2026, % of Revenue 36
Figure 13. Contribution to North America 2020-2026 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%) 37
Figure 14. North America Active Pharmaceutical Ingredients (API) Market: Synthetic API, 2015-2026, $ bn 38
Figure 15. North America Active Pharmaceutical Ingredients (API) Market: Branded Synthetic API, 2015-2026, $ bn 39
Figure 16. North America Active Pharmaceutical Ingredients (API) Market: Generic Synthetic API, 2015-2026, $ bn 40
Figure 17. North America Active Pharmaceutical Ingredients (API) Market: Biotech API, 2015-2026, $ bn 41
Figure 18. North America Active Pharmaceutical Ingredients (API) Market: Monoclonal Antibodies, 2015-2026, $ bn 43
Figure 19. North America Active Pharmaceutical Ingredients (API) Market: Recombinant Proteins, 2015-2026, $ bn 44
Figure 20. North America Active Pharmaceutical Ingredients (API) Market: Vaccines, 2015-2026, $ bn 45
Figure 21. North America Active Pharmaceutical Ingredients (API) Market: Other Biotech APIs, 2015-2026, $ bn 46
Figure 22. North America Active Pharmaceutical Ingredients (API) Market: Innovative Biologic API, 2015-2026, $ bn 48
Figure 23. North America Active Pharmaceutical Ingredients (API) Market: Generic Biosimilar API, 2015-2026, $ bn 49
Figure 24. North America Active Pharmaceutical Ingredients (API) Market: Mammalian Expression, 2015-2026, $ bn 51
Figure 25. North America Active Pharmaceutical Ingredients (API) Market: Microbial Expression, 2015-2026, $ bn 52
Figure 26. North America Active Pharmaceutical Ingredients (API) Market: Yeast Expression, 2015-2026, $ bn 53
Figure 27. North America Active Pharmaceutical Ingredients (API) Market: Insect Expression, 2015-2026, $ bn 54
Figure 28. North America Active Pharmaceutical Ingredients (API) Market: Other Expression Technologies, 2015-2026, $ bn 55
Figure 29. North America Active Pharmaceutical Ingredients (API) Market: HPAPI, 2015-2026, $ bn 56
Figure 30. North America Active Pharmaceutical Ingredients (API) Market: Branded HPAPI, 2015-2026, $ bn 57
Figure 31. North America Active Pharmaceutical Ingredients (API) Market: Generic HPAPI, 2015-2026, $ bn 58
Figure 32. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2019-2026, % of Revenue 59
Figure 33. Contribution to North America 2020-2026 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%) 60
Figure 34. North America Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing, 2015-2026, $ bn 61
Figure 35. North America Active Pharmaceutical Ingredients (API) Market: Branded Captive API, 2015-2026, $ bn 62
Figure 36. North America Active Pharmaceutical Ingredients (API) Market: Generic Captive API, 2015-2026, $ bn 63
Figure 37. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing, 2015-2026, $ bn 64
Figure 38. North America Active Pharmaceutical Ingredients (API) Market: Branded Merchant API, 2015-2026, $ bn 66
Figure 39. North America Active Pharmaceutical Ingredients (API) Market: Generic Merchant API, 2015-2026, $ bn 67
Figure 40. North America Active Pharmaceutical Ingredients (API) Market: Merchant Synthetic API, 2015-2026, $ bn 69
Figure 41. North America Active Pharmaceutical Ingredients (API) Market: Merchant Biotech API, 2015-2026, $ bn 70
Figure 42. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2019-2026, % of Revenue 71
Figure 43. Contribution to North America 2020-2026 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 72
Figure 44. North America Active Pharmaceutical Ingredients (API) Market: Infectious Diseases, 2015-2026, $ bn 73
Figure 45. North America Active Pharmaceutical Ingredients (API) Market: Oncology, 2015-2026, $ bn 74
Figure 46. North America Active Pharmaceutical Ingredients (API) Market: Ophthalmology , 2015-2026, $ bn 75
Figure 47. North America Active Pharmaceutical Ingredients (API) Market: Cardiovascular Disorders, 2015-2026, $ bn 76
Figure 48. North America Active Pharmaceutical Ingredients (API) Market: Central Nervous System, 2015-2026, $ bn 77
Figure 49. North America Active Pharmaceutical Ingredients (API) Market: Pulmonary Disorders, 2015-2026, $ bn 78
Figure 50. North America Active Pharmaceutical Ingredients (API) Market: Orthopedics, 2015-2026, $ bn 79
Figure 51. North America Active Pharmaceutical Ingredients (API) Market: Other Applications, 2015-2026, $ bn 80
Figure 52. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2019-2026, % of Revenue 81
Figure 53. Contribution to North America 2020-2026 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 82
Figure 54. North America Active Pharmaceutical Ingredients (API) Market: Branded Prescription Drugs, 2015-2026, $ bn 83
Figure 55. North America Active Pharmaceutical Ingredients (API) Market: Generic Prescription Drugs, 2015-2026, $ bn 84
Figure 56. North America Active Pharmaceutical Ingredients (API) Market: OTC Drugs, 2015-2026, $ bn 85
Figure 57. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Country, 2019 and 2026, % of Revenue 87
Figure 58. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value ($ bn) and Share (%) 88
Figure 59. U.S. Active Pharmaceutical Ingredients (API) Market, 2015-2026, $ bn 90
Figure 60. Canada Active Pharmaceutical Ingredients (API) Market, 2015-2026, $ bn 93
Figure 61. Active Pharmaceutical Ingredients (API) Market in Mexico, 2015-2026, $ bn 95
Figure 62. Growth Stage of North America Active Pharmaceutical Ingredients (API) Industry over the Forecast Period 97
Table 1. Snapshot of North America Active Pharmaceutical Ingredients (API) Market, 2019-2026 19
Table 2. Main Product Trends and Market Opportunities in North America Active Pharmaceutical Ingredients (API) Market 28
Table 3. North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 36
Table 4. North America Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2015-2026, $ bn 38
Table 5. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2015-2026, $ bn 42
Table 6. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2015-2026, $ bn 47
Table 7. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2015-2026, $ bn 50
Table 8. North America Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2015-2026, $ bn 56
Table 9. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 59
Table 10. North America Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2015-2026, $ bn 61
Table 11. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2015-2026, $ bn 65
Table 12. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2015-2026, $ bn 68
Table 13. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 71
Table 14. North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2015-2026, $ bn 81
Table 15. North America Active Pharmaceutical Ingredients (API) Market by Country, 2015-2026, $ bn 87
Table 16. U.S. Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 91
Table 17. U.S. Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 91
Table 18. U.S. Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 91
Table 19. Canada Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 94
Table 20. Canada Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 94
Table 21. Canada Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 94
Table 22. Mexico Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 96
Table 23. Mexico Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 96
Table 24. Mexico Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 96
Table 25. AbbVie Inc.: Company Snapshot 101
Table 26. AbbVie Inc.: Business Segmentation 101
Table 27. AbbVie Inc.: Product Portfolio 102
Table 28. AbbVie Inc.: Revenue, 2016-2018, $ bn 102
Table 29. AbbVie Inc.: Recent Developments 102
Table 30. Risk Evaluation for Investing in North America Market, 2019-2026 123
Table 31. Critical Success Factors and Key Takeaways 126
Safe and Secure SSl Encryption
Licensing options
2480
USD
You can select one of these options upon checking out
Allows one individual to access the purchased report
Allows up to five individuals to access the purchased report
Allows all employees of an organization to access the purchased report. Internal sharing only
Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral
North America: +1 201 793 8545 Europe: +44 20 8089 0049 Asia-Pacific: +91 7878231309
Email us on:- sales@bonafideresearch.com
Order Placed (25 September, 2023)
Notify To Team (25 September, 2023)
Report updation (26 September, 2023)
Report Quality Check (26 September, 2023)
Report Dispatch (27 September, 2023)
Hard Copy
Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
We offer $1000 worth of FREE customization at the time of purchase
80% of the clinet request tailor made solution, how can we help you?
Avail customized purchase options to meet your exact research needs:
READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.
CEO
Vivek Arora
BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!
EXECUTIVE DIRECTOR
Rahul Roy
THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.
SALES DIRECTOR
Arjun Prasad
THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH
President
Manish Verma
Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
MARKETING DIRECTOR
Gautam Saxena
The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.
PRODUCT MANAGER
Tom Stone
I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.
Associate Director
Mark Wood
North America active pharmaceutical ingredients (API) market is expected to grow by 5.7% annually in the forecast period and reach $101.03 billion by 2026 driven by the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic. Highlighted with 31 tables and 62 figures, this 128-page report “North America Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country. Based on Synthesis, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section. Synthetic API • Branded Synthetic API • Generic Synthetic API Biotech API by Drug Type: • Monoclonal Antibodies • Recombinant Proteins • Vaccines • Other Biotech APIs Biotech API by Customer Base: • Innovative Biologic API • Generic Biosimilar API Biotech API by Expression Technology: • Mammalian Expression • Microbial Expression • Yeast Expression • Insect Expression • Other Expression Technologies HPAPI • Branded HPAPI • Generic HPAPI Based on Manufacturing Process, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section. Captive Manufacturing • Branded Captive API • Generic Captive API Merchant Manufacturing by Drug Type: • Branded Merchant API • Generic Merchant API Merchant Manufacturing by Drug Synthesis: • Merchant Synthetic API • Merchant Biotech API Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Orthopedics • Other Applications Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section. • Branded Prescription Drugs • Generic Prescription Drugs • OTC Drugs Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each aforementioned country, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AbbVie Inc. Astrazeneca Aurobindo Pharma Ltd. Bayer Healthcare Bioniche Animal Health Boehringer Ingelheim Bristol-Myers Squibb Ceva Animal Health, Inc. Elanco Animal Health Eli Lilly and Company F. Hoffmann-La Roche Glaxosmithkline PLC Heska Co. Lonza Group Merck & Co., Inc. Novartis International AG Pfizer, Inc. Ranbaxy Laboratories Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More